Scholarlink

Purpose of Review <p>Chemotherapy frequently causes cutaneous toxicities necessitating dose adjustments or treatment cessation. Toxic erythema of chemotherapy (TEC) encompasses a spectrum of skin toxicities characterized by painful erythematous and edematous (and often bullous or desquamative) eruptions commonly affecting the palms, soles, and intertriginous and flexural skin. Severe cases may mimic Stevens-Johnson syndrome/toxic epidermal necrolysis or graft-versus-host disease. Historically subtyped into hand-foot syndrome or malignant intertrigo, overlapping clinical and histological features now favor a unified classification under the umbrella of TEC to facilitate more precise communication and management.</p> Recent Findings <p>The increasing use of antibody-drug conjugates has heightened the incidence of TEC. Emerging therapeutic strategies include cyclooxygenase (COX) inhibitors and oral high-dose vitamin D, which has been shown to rapidly ameliorate the symptoms and erythema associated with TEC.</p> Summary <p>TEC is characterized by specific clinicopathologic findings and requires prompt identification and intervention to minimize oncologic treatment disruptions and improve quality of life for patients with cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Toxic Erythema of Chemotherapy: Updates in Evaluation and Management

  • 期刊论文

  • 发表日期：

    2025年7月15日

查看全文
  • Nadean F. Alnajjar,
  • Ryan Chen,
  • Mary Jane Zimarowski,
  • Christopher Iriarte

摘要

Purpose of Review

Chemotherapy frequently causes cutaneous toxicities necessitating dose adjustments or treatment cessation. Toxic erythema of chemotherapy (TEC) encompasses a spectrum of skin toxicities characterized by painful erythematous and edematous (and often bullous or desquamative) eruptions commonly affecting the palms, soles, and intertriginous and flexural skin. Severe cases may mimic Stevens-Johnson syndrome/toxic epidermal necrolysis or graft-versus-host disease. Historically subtyped into hand-foot syndrome or malignant intertrigo, overlapping clinical and histological features now favor a unified classification under the umbrella of TEC to facilitate more precise communication and management.

Recent Findings

The increasing use of antibody-drug conjugates has heightened the incidence of TEC. Emerging therapeutic strategies include cyclooxygenase (COX) inhibitors and oral high-dose vitamin D, which has been shown to rapidly ameliorate the symptoms and erythema associated with TEC.

Summary

TEC is characterized by specific clinicopathologic findings and requires prompt identification and intervention to minimize oncologic treatment disruptions and improve quality of life for patients with cancer.